natgillin/translations-raw huggingface dataset:
However, data suggested a 20% higher levetiracetam clearance in children taking enzyme-inducing antiepileptic medicinal products. 
Vendar pa podatki nakazujejo, da je pri otrocih, ki jemljejo antiepileptična zdravila, ki inducirajo encime, povečan očistek levetiracetama za 20 %.
Levetiracetam induces seizure protection in a broad range of animal models of partial and primary generalised seizures without having a pro-convulsant effect. 
Levetiracetam povzroči zaščito pred parcialnimi in primarno generaliziranimi napadi pri širokem spektru živalskih modelov in nima prokonvulzivnega učinka.
• weakness, feel light-headed or dizzy or have difficulty breathing, as these may be signs of a serious allergic (anaphylactic) reaction 
• šibkost, vrtoglavico ali omotico ali težave z dihanjem, saj so to lahko znaki resne alergijske (anafilaktične) reakcije
To use this dosing table, an estimate of the patient's creatinine clearance (CLcr) in ml/min is needed. 
Za uporabo te preglednice je treba predhodno oceniti bolnikov očistek kreatinina (CLcr) v ml/min.
The pharmacokinetic profile is linear with low intra- and inter-subject variability. 
Ima linearni farmakokinetični profil, z majhno intra- in interindividualno variabilnostjo.
• rhabdomyolysis (breakdown of muscle tissue) and associated blood creatine phosphokinase increase. 
• rabdomioliza (razgradnja mišičnega tkiva) in z njo povezano zvišanje kreatin fosfokinaze v krvi.
The intravenous formulation is an alternative to your oral administration. 
Intravenska oblika je alternativa vaši peroralni uporabi.
In man, an activity in both partial and generalised epilepsy conditions (epileptiform discharge/photoparoxysmal response) has confirmed the broad spectrum pharmacological profile of levetiracetam. 
Delovanje na parcialne in generalizirane epileptične napade (epileptiformno proženje/fotoparoksizmalen odgovor) potrjuje njegov širok spekter farmakološkega profila levetiracetama pri ljudeh.
A retrospective assessment of pharmacokinetic interactions in children and adolescents with epilepsy (4 to 17 years) confirmed that adjunctive therapy with orally administered levetiracetam did not influence the steady-state serum concentrations of concomitantly administered carbamazepine and valproate. 
Retrospektivna ocena o farmakokinetičnih interakcijah pri otrocih in mladostnikih z epilepsijo (od 4 do 17 let) je potrdila, da dopolnilna terapija s peroralno uporabljenim levetiracetamom ni vplivala na koncentracije v serumu v stanju dinamičnega ravnovesja pri sočasnem dajanju karbamazepina in valproata.
The time independent pharmacokinetic profile of levetiracetam was also confirmed following 1,500 mg intravenous infusion for 4 days with twice daily dosing. 
Potrjen je bil tudi časovno neodvisen farmakokinetični profil levetiracetama pri intravenski infuziji 1.500 mg dvakrat dnevno 4 dni.
The primary metabolite is inactive. 
Njegov primarni presnovek ni aktiven.
What Levetiracetam Hospira is and what it is used for 
Kaj je zdravilo Levetiracetam Hospira in za kaj ga uporabljamo
This is more likely at the beginning of treatment or after an increase in the dose. 
Zaspanost se največkrat pojavlja na začetku zdravljenja ali po povečanju odmerka.
Two minor metabolites were also identified. 
Odkrili so še dva manj pomembna presnovka.
5 How to store Levetiracetam Hospira 6 Contents of the pack and other information 
5 Shranjevanje zdravila Levetiracetam Hospira 6 Vsebina pakiranja in dodatne informacije
The renal clearance of levetiracetam and ucb L057 is 0.6 and 4.2 ml/min/kg respectively indicating that levetiracetam is excreted by glomerular filtration with subsequent tubular reabsorption and that the primary metabolite is also excreted by active tubular secretion in addition to glomerular filtration. 
Ledvični očistek levetiracetama 0,6 ml/min/kg in njegovega primarnega presnovka ucb L057 4,2 ml/min/kg kažeta na to, da se levetiracetam izloča z glomerulno filtracijo, ki ji sledi tubularna reabsorpcija, primarni presnovek pa se poleg glomerulne filtracije izloča tudi z aktivno tubularno sekrecijo.
• symptoms such as low urine volume, tiredness, nausea, vomiting, confusion and swelling in the legs, ankles or feet, as this may be a sign of sudden decrease of kidney function 
• simptome kot so majhen volumen urina, utrujenost, slabost, bruhanje, zmedenost in otekanje nog, gležnjev ali stopal saj so lahko to znaki nenadnega zmanjšanja delovanja ledvic
In addition, levetiracetam does not affect the in vitro glucuronidation of valproic acid. 
Levetiracetam in vitro prav tako ne vpliva na glukuronidacijo valprojske kisline.
Levetiracetam Hospira concentrate is for intravenous use only and the recommended dose must be diluted in at least 100 ml of a compatible diluent and administered intravenously as a 15-minute intravenous infusion (see section 6.6). 
Zdravilo Levetiracetam Hospira koncentrat je samo za intravensko uporabo, priporočeni odmerek mora biti razredčen v vsaj 100 ml kompatibilnega topila in uporabljen intravensko kot 15-minutna intravenska infuzija (glejte poglavje 6.6).
At 3,600 mg/kg/day, in only one of the 2 EFD studies, there was a slight decrease in foetal weight associated with a marginal increase in skeletal variations/minor anomalies. 
Pri 3.600 mg/kg/dan se je samo v eni od dveh študij embriofetalnega razvoja telesna masa plodu zanemarljivo zmanjšala v povezavi z marginalnim povečanjem skeletnih sprememb/manjših anomalij.
The active substance, levetiracetam, is a pyrrolidone derivative (S-enantiomer of α-ethyl-2-oxo-1-pyrrolidine acetamide), chemically unrelated to existing antiepileptic active substances. 
Učinkovina levetiracetam je pirolidonski derivat (S-enantiomer -etil-2-okso-1-pirolidinacetamida), ki kemično ni podoben drugim antiepileptičnim učinkovinam.
Levetiracetam is not extensively metabolised in humans. 
Levetiracetam se pri ljudeh ne presnavlja obsežno.
• a widespread rash with blisters and peeling skin, particularly around the mouth, nose, eyes and genitals (Stevens-Johnson syndrome) 
• široko razširjen izpuščaj z mehurji in luščenjem kože, še posebej okoli ust, nosu, oči in v predelu spolovil (Stevens-Johnsonov sindrom)
Do not use this medicine after the expiry date stated on the vial and carton box after EXP: The expiry date refers to the last day of the month. 
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na viali in škatli poleg oznake EXP:.
Levetiracetam Hospira is for intravenous use. 
Zdravilo Levetiracetam Hospira je za intravensko uporabo.
What you need to know before you are given Levetiracetam Hospira 
Kaj morate vedeti, preden boste prejeli zdravilo Levetiracetam Hospira
Peak plasma concentration was observed 0.5 to 1.0 hour after dosing. 
Največja plazemska koncentracija je bila dosežena med 0,5 in 1 uro po odmerku.
It is therefore recommended to adjust the maintenance daily dose of levetiracetam, based on creatinine clearance in patients with moderate and severe renal impairment (see section 4.2). 
Zato je priporočljivo dnevni vzdrževalni odmerek levetiracetama pri bolnikih z zmerno in hudo ledvično okvaro prilagoditi očistku kreatinina (glejte poglavje 4.2).
• skin rash, which may form blisters and looks like small targets (central dark spots surrounded by a paler area, with a dark ring around the edge) (erythema multiforme), a widespread rash with blisters and peeling skin, particularly around the mouth, nose, eyes and genitals (Stevens-Johnson syndrome), and a more severe form causing skin peeling in more than 30% of the body surface (toxic epidermal necrolysis); 
• kožni izpuščaj, ki lahko tvori mehurčke in izgleda kot majhne tarče (na sredini temne pike, obkrožene s svetlejšim delom in s temnim krogom na robu) (multiformni eritem), široko razširjen izpuščaj z mehurčki in luščenjem kože, še posebej okoli ust, nosu, oči in v predelu spolovil (Stevens-Johnsonov sindrom) in bolj huda oblika, ki povzroči luščenje kože na več kot 30 % telesne površine (toksična epidermalna nekroliza);
5 ml glass vial (type I) with bromobutyl coated rubber stoppers and an aluminium flip-off seal. 
5 ml steklena viala (tip I) z bromobutilnim gumijastim zamaškom in aluminijasto zaporko s ploščico.
• Sodium chloride 9 mg/ml (0.9%) solution for injection 
• natrijev klorid 9 mg/ml (0,9 %) raztopina za injiciranje
The patients were randomized to carbamazepine CR 400-1,200 mg/day or levetiracetam 1,000-3,000 mg/day, the duration of the treatment was up to 121 weeks depending on the response. 
Bolniki so randomizirano prejemali 400-1.200 mg karbamazepina z nadzorovanim sproščanjem (CR) na dan ali 1.000-3.000 mg levetiracetama na dan, trajanje zdravljenja pa je bilo do 121 tednov oziroma odvisno od odziva.
• a skin rash which may form blisters and look like small targets (central dark spots surrounded by a paler area, with a dark ring around the edge) (erythema multiforme) 
• kožni izpuščaj, ki lahko tvori mehurje in po videzu spominja na majhne tarče (na sredini temne pike, obkrožene s svetlejšim delom in s temnim krogom na robu) (multiformni eritem)
Each carton contains 10 or 25 vials. 
Ena škatla vsebuje 10 ali 25 vial.
In paediatric patients (4 to 16 years of age), levetiracetam efficacy was established in a double-blind, placebo-controlled study, which included 198 patients and had a treatment duration of 14 weeks. 
Pri pediatričnih bolnikih (od 4 do 16 let) je bila učinkovitost levetiracetama dokazana v dvojno slepi, s placebom nadzorovani študiji, ki je vključevala 198 bolnikov in trajala 14 tednov.
The adverse reaction profile presented below is based on the analysis of pooled placebo-controlled clinical trials with all indications studied, with a total of 3,416 patients treated with levetiracetam. 
Profil neželenih učinkov, ki je opisan spodaj, temelji na analizi združenih s placebom nadzorovanih kliničnih preskušanj za vse preučevane indikacije, v katerih so z levetiracetamom zdravili 3416 bolnikov.
For children with renal impairment, levetiracetam dose needs to be adjusted based on the renal function as levetiracetam clearance is related to renal function. 
Pri otrocih z ledvično okvaro je treba odmerek levetiracetama prilagoditi glede na delovanje ledvic, kajti z njihovim delovanjem je povezan tudi očistek levetiracetama.
• diplopia (double vision), vision blurred; 
• diplopija (dvojni vid), zamegljen vid;
The dose level of 1800 mg/kg/day induced a marked maternal toxicity and a decrease in foetal weight associated with increased incidence of foetuses with cardiovascular/skeletal anomalies. 
Odmerki 1.800 mg/kg/dan so sprožili izrazito toksičnost pri samicah in zmanjšanje telesne mase zarodka, povezano s povečanjem pogostnosti zarodkov s kardiovaskularnimi/skeletnimi anomalijami.
You can switch from the filmcoated tablets or from the oral solution to the intravenous formulation or reverse directly without dose adaptation. 
Prehod od filmsko obloženih tablet ali od peroralne raztopine k intravenski obliki ali obratno, je lahko neposreden brez prilagajanja odmerka.
If you have any symptoms of depression and/or suicidal ideation, please contact your doctor. 
Če imate kakršne koli simptome depresije ali misli o samomoru ali oboje, se posvetujte z zdravnikom.
Levetiracetam is an antiepileptic medicine (a medicine used to treat seizures (fits) in epilepsy). 
Levetiracetam je zdravilo proti epilepsiji (zdravilo za zdravljenje epileptičnih napadov).
Breast-feeding is not recommended during treatment. 
Med zdravljenjem ni priporočljivo dojiti.
For doctors and nurses, more detailed direction for the proper use of Levetiracetam Hospira is provided in section 6. 
Za zdravnike in medicinske sestre so podrobna navodila za uporabo zdravila Levetiracetam Hospira navedena v poglavju 6.
Levetiracetam 1,000 mg daily did not influence the pharmacokinetics of oral contraceptives (ethinylestradiol and levonorgestrel); endocrine parameters (luteinizing hormone and progesterone) were not modified. 
Levetiracetam v odmerku 1.000 mg na dan ni vplival na farmakokinetiko peroralnih kontraceptivov (etinilestradiola in levonorgestrela); endokrini parametri (luteinizirajoči hormon in progesteron) se niso spremenili.
However, based on the pharmacokinetic characteristics of levetiracetam, the pharmacokinetics in adults after intravenous administration and the pharmacokinetics in children after oral administration, the exposure (AUC) of levetiracetam is expected to be similar in paediatric patients aged 4 to 12 years after intravenous and oral administration. 
Vendar je na osnovi farmakokinetičnih znaličnosti levetiracetama, farmakokinetike pri odraslih po intravenskem dajanju in farmakokinetike pri otrocih po peroralnem dajanju, pričakovati pri otrocih od 4 do 12 let podobno razpoložljivost (AUC) levetiracetama po intravenskem in peroralnem dajanju.
Vial of 5 ml 
Viala s 5 ml
Dose in children 50 kg or greater is the same as in adults. 
Pri otrocih, ki so težki 50 kg ali več, je odmerjanje enako kot pri odraslih.
• depression, hostility or aggression, anxiety, insomnia, nervousness or irritability; 
• depresija, sovražnost ali agresivnost, anksioznost, nespečnost, živčnost ali razdražljivost;
• decreased blood sodium concentration; 
• znižana koncentracija natrija v krvi;
Following repeated oral dose administration (20 to 60 mg/kg/day) to epileptic children (4 to 12 years), levetiracetam was rapidly absorbed. 
Po uporabi večkratnih peroralnih odmerkov (od 20 do 60 mg/kg/dan) pri otrocih z epilepsijo (od 4 do 12 let) se je levetiracetam hitro absorbiral.
58.3% of the levetiracetam treated patients and 23.3% of the patients on placebo had at least a 50% reduction in myoclonic seizure days per week. 
58,3 % bolnikov, ki so se zdravili z levetiracetamom, in 23,3 % bolnikov, ki so prejemali placebo, je imelo vsaj 50-odstotno zmanjšanje števila dni z miokloničnimi napadi na teden.
In the elderly, the half-life is increased by about 40% (10 to 11 hours). 
Zaradi zmanjšanega delovanja ledvic se pri starejših razpolovni čas podaljša za približno 40 % (10 do 11 ur) (glejte poglavje 4.2).
In a pooled analysis, the percentage of patients who achieved 50% or greater reduction from baseline in the partial onset seizure frequency per week at stable dose (12/14 weeks) was of 27.7%, 31.6% and 41.3% for patients on 1,000, 2,000 or 3,000 mg levetiracetam respectively and of 12.6% for patients on placebo. 
Delež bolnikov iz zbranih analiz, pri katerih je bilo doseženo 50 ali več odstotno zmanjšanje pogostnosti parcialnih napadov na teden pri stalnem odmerku (12/14 tednov), je bil 27,7 % pri bolnikih, ki so prejemali 1.000 mg, 31,6 % pri bolnikih, ki so prejemali 2.000 mg in 41,3 % pri bolnikih, ki so prejemali 3.000 mg levetiracetama, ter 12,6 % pri bolnikih, ki so prejemali placebo.
• flu-like symptoms and a rash on the face followed by an extended rash with a high temperature, increased levels of liver enzymes seen in blood tests and an increase in a type of white blood cell (eosinophilia) and enlarged lymph nodes (Drug Reaction with Eosinophilia and Systemic Symptoms [DRESS]). 
• gripi podobne simptome in izpuščaj na obrazu, ki se v nadaljevanju razširi in ga spremlja visoka temperatura, zvišane vrednosti jetrnih encimov pri krvnih testih in povečanje števila določenega tipa belih krvnih celic (eozinofilija) ter povečane bezgavke (reakcija na zdravilo z eozinofilijo in sistemskimi simptomi [DRESS])
See the package leaflet for further information. 
Za podrobnejše informacije glejte priloženo navodilo za uporabo.
Levetiracetam Hospira concentrate for solution for infusion is packed in a cardboard box containing 10 or 25 vials of 5 ml. 
Zdravilo Levetiracetam Hospira koncentrat za raztopino za infundiranje je pakirano v škatle po 10 ali 25 5 ml vial.
In this study, the patients received levetiracetam as a fixed dose of 60 mg/kg/day (with twice a day dosing). 
V tej študiji so bolniki prejemali stalen odmerek 60 mg/kg/dan (odmerjanje dvakrat na dan).
Add-on therapy for infants and children less than 4 years The safety and efficacy of levetiracetam concentrate for solution for infusion in infants and children less than 4 years have not been established. 
Dopolnilno zdravljenje za dojenčke in otroke, mlajše od 4 let Varnost in učinkovitost levetiracetama v obliki koncentrata za raztopino za infundiranje pri dojenčkih in pri otrocih, mlajših od 4 let, nista bili dokazani.
In a study reflecting clinical practice, the concomitant antiepileptic medication could be withdrawn in a limited number of patients who responded to levetiracetam adjunctive therapy (36 adult patients out of 
V študiji, ki je odražala klinično prakso, je bilo mogoče pri omejenem številu bolnikov, ki so se odzvali na dopolnilno zdravljenje z levetiracetamom (36 od 69 odraslih bolnikov), prekiniti sočasno antiepileptično zdravljenje.
If levetiracetam has to be discontinued it is recommended to withdraw it gradually (e.g. in adults and adolescents weighing more than 50 kg: 500 mg decreases twice daily every two to four weeks; in children and adolescents weighting less than 50 kg: dose decrease should not exceed 10 mg/kg twice daily every two weeks). 
Če je treba zdravljenje z levetiracetamom prekiniti, je priporočljivo zdravljenje opustiti postopno (npr. pri odraslih in mladostnikih, težkih več kot 50 kg: zmanjševanje odmerka za 500 mg dvakrat na dan na vsaka dva tedna do štiri tedne; pri otrocih in mladostnikih s telesno maso manj kot 50 kg: zmanjšanje odmerka ne sme preseči 10 mg/kg dvakrat na dan vsaka dva tedna).
If you are allergic to levetiracetam, pyrrolidone derivatives or any of the other ingredients of this medicine (listed in Section 6). 
Ne uporabljajte zdravila Levetiracetam Hospira če ste alergični na levetiracetam, pirolidonske derivate ali katero koli sestavino tega zdravila (navedeno v poglavju 6).
There is no evidence for any relevant gender, race or circadian variability. 
Med spoloma, rasami ali cirkadiano ni znakov pomembne variabilnosti.
Levetiracetam Hospira is used: on its own in adults and adolescents from 16 years of age with newly diagnosed epilepsy, to treat a certain form of epilepsy. 
Zdravilo Levetiracetam Hospira se uporablja: samostojno za zdravljenje pri odraslih in mladostnikih od 16. leta starosti z na novo diagnosticirano epilepsijo, za zdravljenje določene oblike epilepsije.
The pharmacokinetic profile is comparable in healthy volunteers and in patients with epilepsy. 
Farmakokinetični profil pri bolnikih z epilepsijo je primerljiv s farmakokinetičnim profilom pri zdravih prostovoljcih.
Probenecid (500 mg four times daily), a renal tubular secretion blocking agent, has been shown to inhibit the renal clearance of the primary metabolite, but not of levetiracetam. 
Ugotovili so, da probenecid (500 mg štirikrat na dan), ki preprečuje ledvično tubularno sekrecijo, zavre ledvični očistek primarnega presnovka, ne pa levetiracetama.
This finding suggests that the interaction between levetiracetam and the synaptic vesicle protein 2A seems to contribute to the antiepileptic mechanism of action of the medicinal product. 
Ta odkritja kažejo, da bi lahko interakcija med levetiracetamom in sinaptičnim vezikularnim proteinom 2A prispevala k antiepileptičnemu delovanju zdravila.
It was concluded that levetiracetam was not different (non-inferior) from placebo with regard to the change from baseline of the Leiter-R Attention and Memory, Memory Screen Composite score in the per-protocol population. 
Ugotovili so, da se levetiracetam pri populaciji po protokolu ne razlikuje (ni manjvredno) od placeba glede spremembe od začetnih vrednosti rezultatov testiranja spomina in pozornosti (Leiter-R Attention and Memory, Memory Screen Composite).
In patients with severely impaired hepatic function, assessment of renal function is recommended before dose selection (see section 4.2). 
Pri bolnikih z okvarjenim delovanjem jeter je pred izbiro odmerka priporočljivo oceniti delovanje ledvic (glejte poglavje 4.2).
From a microbiological point of view, unless the method of dilution precludes the risk of microbial contamination, the product should be used immediately. 
Z mikrobiološkega stališča je zdravilo treba uporabiti takoj, razen, če metoda redčenja izključuje tveganje za mikrobiološko kontaminacijo.
The CLcr in ml/min/1.73 m2 may be estimated from serum creatinine (mg/dl) determination, for young adolescents and children using the following formula (Schwartz formula): 
CLcr v ml/min/1,73 m2 je pri mlajših mladostnikih in otrocih mogoče oceniti iz koncentracije kreatinina v serumu (mg/dl) z uporabo naslednje formule (po Schwartzevi formuli):
Concentrate for solution for infusion (sterile concentrate). 
koncentrat za raztopino za infundiranje (sterilni koncentrat)
The recommended dose must be diluted in at least 100 ml of a compatible diluent and infused over 15-minutes. 
Priporočeni odmedrek se mora razredčiti v vsaj 100 ml kompatibilnega topila in infundirati 15 minut.
10 vials 25 vials 
10 vial 25 vial
The risk of anorexia is higher when levetiracetam is co-administered with topiramate. 
Tveganje za pojav anoreksije je večje pri sočasni uporabi levetiracetama in topiramata.
The pharmacokinetics in paediatric patients has not been investigated after intravenous administration. 
Pri otrocih niso raziskovali farmakokinetike po intravenskem dajanju.
Levetiracetam and related analogues show a rank order of affinity for binding to the synaptic vesicle protein 2A which correlates with the potency of their anti-seizure protection in the mouse audiogenic model of epilepsy. 
Levetiracetam in sorodni analogi kažejo vrstni red afinitete za vezavo na sinaptični vezikularni protein 2A, ki korelira z jakostjo antiepileptične zaščite pri mišjem audiogenem modelu epilepsije.
Levetiracetam Hospira concentrate for solution for infusion (sterile concentrate) is a clear, colourless solution. 
Zdravilo Levetiracetam Hospira koncentrat za raztopino za infundiranje (sterilni koncentrat) je bistra, brezbarvna raztopina.
This medicinal product contains 2.5 mmol (or 57 mg) sodium per maximum single dose (0.8 mmol (or 19 mg) per vial). 
To zdravilo vsebuje 2,5 mmol (ali 57 mg) natrija v največjem enkratnem odmerku (0,8 mmol (ali 19 mg) na vialo).
In this study, levetiracetam dose was 3,000 mg/day for adults and adolescents or 60 mg/kg/day for children, given in 2 divided doses. 
V tej študiji je bil odmerek levetiracetama za odrasle in mladostnike 3.000 mg na dan, za otroke pa 60 mg/kg/dan, razdeljen na dva odmerka.
Levetiracetam can be used during pregnancy, only if after careful assessment it is considered necessary by your doctor. 
Zdravilo Levetiracetam Hospira se lahko med nosečnostjo uporablja samo, če zdravnik po skrbni oceni ugotovi, da je to potrebno.
CLcr (ml/min) = ----------------------------------------- (x 0.85 for women) 72 x serum creatinine (mg/dl) 
[140 - starost (leta)] x masa (kg) CLcr (ml/min) = ---------------------------------------------------- (x 0,85 za ženske) 72 x koncentracija kreatinina v serumu (mg/dl)
Levetiracetam therapy can be initiated with either intravenous or oral administration. 
Zdravljenje z levetiracetamom lahko začnemo z intravensko ali peroralno uporabo.
A peri- and post-natal development study was performed in rats with levetiracetam doses of 70, 350 and 1,800 mg/kg/day. 
Peri- in postnatalne razvojne študije z levetiracetamom pri podganah so izvedli pri odmerkih od 70, 350 in 1.800 mg/kg/dan.
• anorexia (loss of appetite); 
anoreksija (izguba teka);
Dose in children and adolescents 50 kg or more is the same as in adults. 
Pri otrocih in mladostnikih, težkih 50 kg ali več, je odmerjanje enako kot pri odraslih.
If stopping treatment, as with other antiepileptic medicines, Levetiracetam Hospira should be discontinued gradually to avoid an increase of seizures. 
Tako kot pri vseh protiepileptičnih zdravilih je tudi pri zdravilu Levetiracetam Hospira treba zdravljenje opustiti postopoma, da se število napadov ne bi povečalo.
The total daily dose and frequency of administration should be maintained. 
Celokupni dnevni odmerek in pogostost uporabe morata ostati enaka.
35 infants aged less than 1 year with partial onset seizures have been exposed in placebo-control clinical studies of which only 13 were aged < 6 months. 
35 dojenčkov, starih manj kot 1 leto, s parcialnimi napadi, od katerih je bilo le 13 starih < 6 mesecev, je bilo vključenih v placebo kontrolirane klinične študije.